Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
We have hit an all time low and have fallen 50% in the last week. Sad times.
This very strange and not good. Someone knows something.
Surely JM isn’t ploughing a significant sum each year for Fortacin not to pay off for him. He has waiting double digit years to see this come to the fore.
Down 20%…… x
So what are your expectations now Italian?
Come on, are we going to see Fortacin in the USA and China by 2025? Are we going to see an SP
Of 0.50 or 0.75 by 2025?!
Hope running out on USA but hopefully China will pull through. I was here for the USA so will be very disappointed.
Thanks Alquemie. We are doomed but we have known that for a while. USA and China not going to happen while Jim Mellon isn’t going to continue keeping RP going. We will close this chat altogether tonight. You years of input have been appreciate.
Best wishes and goodbye.
The money fountain has stopped flowing. .
I am sure you are correct Bignose. I await the rapid rise in the Sp.
It like this line Bignose.
Mind you, If this takes off, which I am sure it will, JM will become a multi-billionaire which will certainly impress all his mates...
Hopefully you have been given the heads up and know more than we do.
I have remained optimistic since buying shares in 2011 but seeing the sp move from 0.79 downwards ever since has been a huge worry. The lack of news and urgency to get the product established in the USA which was going to be the main cash reward is huge concern. Selling in Europe has been a huge flop after an initial promotional push in the UK media. Jim Mellon continues to keep the company running but I am sure he would have thought that Fortacin would have now been selling in decent amounts worldwide by now. Who knows what the future holds but our days could be numbered. I really did think 2023 was going to be the year.
Will we ever get good news here! Years go by and my hope is fading. I thought this year was going to be the one for USA and China. Oh and the Money Fountain! Night.
Due to the up coming high demand in China and USA. Important not to run out!!!!
When do you think we will get our next update on USA or China approval?
Is Dr Mike still involved or has he pulled out? Sure I read he had resigned?
Jim isn’t just going to sink money in hoping there is a positive outcome. He must know that there is a strong possibility of success and the opportunity to make much more than he put in. It has been a long time in the making but profits for us might not be too far away……
So if Jim is now then majority shareholder the SP isn’t going to move unless sales and good or we get licences in USA or China. Jim must be extremely hopefully of this as he has put millions in here.
Hopefully 2023 is the year!!!!!!
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, is pleased to announce that its year-to-date revenues are ahead of the Group's full year 2021 revenue figures. In addition, the Group has a large advanced opportunity in the pipeline which if successful, could provide a further boost to revenue in the short term.
The Group has made good progress towards completing its innovative, next generation TrueVue monitor (the "New Monitor"). The Group's original intention had been to ship the New Monitor and subsequently invoice customers this year. However, regulatory approvals needed before the New Monitor can be launched onto the market will take several more weeks to be completed, including further testing. This delay has been caused by headwinds associated with strains in global supply chains that delayed the start of the approval process, including the completion of the testing for regulatory compliance.
During 2022 Deltex Medical has shown the New Monitor to a number of customers with a view to them purchasing the New Monitor. The Group is pleased to report that interest has been strong, and the Group has already won a tender in respect of the New Monitor at a price point significantly higher than price levels typically achieved for the current monitor. Deltex Medical expects strong demand from its distributors and end-users in relation to replacing legacy monitors, once the New Monitor has been released for sale.
The business has been tightly managed and therefore operating costs are lower than originally anticipated. However, in order to help fund the increased cash requirements associated with the unexpected delay in the launch of the New Monitor, Mr. Nigel Keen, the Company's largest shareholder and Chairman, has agreed to provide further cash support to Deltex Medical, on arm's length commercial terms.
Accordingly, the Board has entered into an agreement with Imperialise Limited, a company controlled by Mr. Nigel Keen, for a loan of £0.25 million by way of extension to the existing £0.5 million standby loan facility that was put in place and announced by the Company on 20 September 2021 and is now fully drawn down. The interest rate on the facility remains at 8% per annum, and it is unsecured. The £0.75 million standby loan facility is repayable in full on or before 31 December 2023.